Immunosyn Corporation Announces 2007 Results, F... (inJanuary 2007 and its stock began tradi...)

Immunosyn Corporation Announces 2007 Results, Files 10KSB

Date:3/31/2008

in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol "IMYN."

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-KSB for its most recent fiscal year recently filed with SEC. The Company assumes no obligation to update the information contained in this press release, whether as a
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Immunosyn Corporation to Present at FSX
2. Immunosyn Corporation Names G. David Criner as CFO
3. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
4. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
5. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
6. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. BioElectronics Corporation Announces Singapore and Malaysia Sales
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds

Post Your Comments:

(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...

(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...

(Date:5/23/2013)... Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City. The presentation is scheduled to begin at ...

(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...

Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2 The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3 Verenium To Present At Two Upcoming Conferences 2 Verenium To Present At Two Upcoming Conferences 3 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3

[0] The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments [0] NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer [0] Verenium To Present At Two Upcoming Conferences [0] SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre

... Genesis Biopharma, Inc. (OTC Bulletin Board: ... therapies, today announced the company,s support of the ... Two or More Unmarketed Investigational Drugs for Use ... companies to collaborate and seek approval for successfully ...

... Health, Inc. (Nasdaq: GHDX) today announced presentation of three ... (1) Gastrointestinal (GI) Cancer Symposium, including one finding that ... recurrence risk in stage II colon cancer, suggesting that ... Recurrence Score® (RS) test as well as T-stage and ...

... 21, 2011 NewLink Genetics Corporation today announced that ... the company,s investigational HyperAcute® Pancreas cancer immunotherapy will be ... of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San ... Title: Effect of the addition of ...

Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium

(Date:5/24/2013)... conference of 500 leading water scientists from around the ... reforms, "in the short span of one or two ... Earth will be living under the handicap of severe ... for which there is no substitute. This handicap will ... The scientists bluntly pointed to chronic underlying problems led ...

(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...

(Date:5/23/2013)... A new report from the Institute of Medicine ... in at least 60 minutes of vigorous or moderate ... than half of American youth meet current evidence-based guidelines ... intensity physical activity daily, according to the report, which ... school for nearly half of their waking hours, the ...

Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2 A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3 A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4 Emory, Georgia Tech receive first human exposome center grant in US 2 Emory, Georgia Tech receive first human exposome center grant in US 3 Schools should provide students with daily physical activity, IOM recommends 2

[0] A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists [0] Emory, Georgia Tech receive first human exposome center grant in US [0] Schools should provide students with daily physical activity, IOM recommends

... The onset of inflammation and infection in a person recovering ... burns can be as deadly as the incident itself. New ... trauma victims may help to predict and better treat such ... issue of the journal PLoS Medicine shows for ...

... Alaska Natives in the Yukon River Basin provide unique ... adaptation strategies for these local communities. The ... the villages of St. Mary,s and Pitka,s Point, Alaska, ... concerns ranging from safety, such as unpredictable weather patterns ...

... at the San Diego Supercomputer Center (SDSC) at the ... the first global camera trap study of mammals, which ... of protected areas to ensure the diversity and survival ... study, led by Jorge Ahumada, an ecologist with the ...

Cached Biology News:Gene flux can foretell survival for trauma patients, Princeton study finds 2 Gene flux can foretell survival for trauma patients, Princeton study finds 3 Gene flux can foretell survival for trauma patients, Princeton study finds 4 Gene flux can foretell survival for trauma patients, Princeton study finds 5 Gene flux can foretell survival for trauma patients, Princeton study finds 6 Gene flux can foretell survival for trauma patients, Princeton study finds 7 Observations of climate change from indigenous Alaskans 2 Observations of climate change from indigenous Alaskans 3 SDSC-developed software used in first global camera trap mammal study 2 SDSC-developed software used in first global camera trap mammal study 3

Gene flux can foretell survival for trauma patients, Princeton study finds Observations of climate change from indigenous Alaskans SDSC-developed software used in first global camera trap mammal study

AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...

BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....

... BD BioCoat Collagen I 60 mm Culture Dishes ... Dishes, tissue-culture treated polystyrene with a uniform application ... Coating : Collagen I ,Surface : ... 21.3 cm2 ,Dim nominal : 60 ...

... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: D H 100 ...

Biology Products:

Rabbit Anti-Human DNase II Polyclonal Antibody, Unconjugated from Calbiochem BD BioCoat Poly-D-Lysine 60 mm Culture Dishes from BD Biosciences - Discovery Labware BD BioCoat Collagen I 60 mm Culture Dishes from BD Biosciences - Discovery Labware Corning C ulture Dishes,100X20 mm,55Cm2,Sterile,6-Pack Carrier (6Pks Of 10 Dishes) from Sigma-Aldrich